Evidence map›Paper›PMID 37443614›Full record

ArticleDiagnostics (Basel, Switzerland)2023

The Role of PET-CT-Guided Metabolic Biopsies in Improving Yield of Inconclusive Anatomical Biopsies: A Review of 5 Years in a Teaching Hospital.

Dharmender Malik, Vineet Pant, Ishita Sen, Parul Thakral, Subha Shankar Das, Virupakshappa Cb

Open access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Robotic arm-assistedEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Robotic Assistance in PET-CT-guided Lung Biopsies: Enhancing Accuracy and Clinical Outcomes.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Dharmender MalikDepartment of Nuclear Medicine, Fortis Memorial Research Institute, Gurgaon 122002, India.
Vineet PantDepartment of Nuclear Medicine, Fortis Memorial Research Institute, Gurgaon 122002, India.
Ishita SenDepartment of Nuclear Medicine, Fortis Memorial Research Institute, Gurgaon 122002, India.
Parul ThakralDepartment of Nuclear Medicine, Fortis Memorial Research Institute, Gurgaon 122002, India.
Subha Shankar DasDepartment of Nuclear Medicine, Fortis Memorial Research Institute, Gurgaon 122002, India.
Virupakshappa CbDepartment of Nuclear Medicine, Fortis Memorial Research Institute, Gurgaon 122002, India.
Fortis Memorial Research Institute · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumour sampling is indispensable to diagnostic and therapeutic decision making. Thus, 18F-FDG PET/CT has the potential to accurately discriminate between viable and non-viable tissues due to its ability to characterise the metabolism of visible tissues. This study's objective was to evaluate the incremental utility of 18F-FDG PET-CT-guided metabolic biopsy in individuals with suspected lesions and a previous negative anatomical biopsy. This study included a total of 190 consecutive patients with probable malignancy and who had experienced a previous unsuccessful anatomical biopsy who underwent PET-CT-guided metabolic biopsy. We retrospectively analysed the patients' medical records and imaging investigations to assess demographics, complications, pathologies, and final clinical diagnoses. Using multivariate logistic regression, correlation between several confounding factors that lead to post-procedural problems was evaluated. Adequate material was obtained in all patients, and 162 (85%) were found to be positive for malignancy with a diagnostic yield of 96.9%. In 25 (13.1%) patients, post-procedural complications were reported, with pneumothorax being the most prevalent issue. In evaluating oncological patients, metabolic biopsy provides a safer alternative therapy with a high diagnostic yield and comparable complications. PET-CT, being an essential component of cancer staging, may serve as a one-stop shop for the management of these patients' conditions.

Indexed as

18F-FDG PET-CTCT-guided biopsiesmetabolic biopsiesoncologypercutaneous biopsiespneumothorax

Identifiers

PMID37443614
PMCPMC10340339
OpenAlexW4382813687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.